Shanghai Henlius Biotech has begun Phase I trials for its HLX15 proposed biosimilar rival to Janssen’s Darzalex (daratumumab) brand in China, targeting the brand’s multiple myeloma indication.
“In accordance with the technical guidelines of development and evaluation of biosimilar drugs and European Medicines Agency guideline on similar...